Cerus Corporation (CERS)
NASDAQ: CERS · Real-Time Price · USD
2.340
+0.020 (0.86%)
At close: Feb 3, 2026, 4:00 PM EST
2.360
+0.020 (0.85%)
After-hours: Feb 3, 2026, 4:49 PM EST
Cerus Revenue
Cerus had revenue of $60.24M in the quarter ending September 30, 2025, with 18.91% growth. This brings the company's revenue in the last twelve months to $225.97M, up 14.18% year-over-year. In the year 2024, Cerus had annual revenue of $201.32M with 7.78% growth.
Revenue (ttm)
$225.97M
Revenue Growth
+14.18%
P/S Ratio
2.22
Revenue / Employee
$316,176
Employees
630
Market Cap
449.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 201.32M | 14.52M | 7.78% |
| Dec 31, 2023 | 186.80M | -1.52M | -0.81% |
| Dec 31, 2022 | 188.32M | 28.80M | 18.05% |
| Dec 31, 2021 | 159.52M | 45.27M | 39.62% |
| Dec 31, 2020 | 114.25M | 20.48M | 21.83% |
| Dec 31, 2019 | 93.77M | 17.72M | 23.30% |
| Dec 31, 2018 | 76.05M | 24.73M | 48.17% |
| Dec 31, 2017 | 51.33M | 12.05M | 30.68% |
| Dec 31, 2016 | 39.28M | 5.05M | 14.76% |
| Dec 31, 2015 | 34.22M | -2.19M | -6.02% |
| Dec 31, 2014 | 36.42M | -3.24M | -8.17% |
| Dec 31, 2013 | 39.66M | 2.87M | 7.80% |
| Dec 31, 2012 | 36.79M | 3.74M | 11.32% |
| Dec 31, 2011 | 33.04M | 9.94M | 42.99% |
| Dec 31, 2010 | 23.11M | 5.13M | 28.51% |
| Dec 31, 2009 | 17.98M | 1.48M | 8.94% |
| Dec 31, 2008 | 16.51M | 5.46M | 49.47% |
| Dec 31, 2007 | 11.04M | -19.27M | -63.56% |
| Dec 31, 2006 | 30.31M | 16.81M | 124.57% |
| Dec 31, 2005 | 13.50M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orthofix Medical | 818.06M |
| Bioventus | 563.83M |
| OrthoPediatrics | 227.41M |
| Standard BioTools | 169.74M |
| RxSight | 142.09M |
| NeuroPace | 94.86M |
| Delcath Systems | 79.60M |
| Sight Sciences | 76.05M |
CERS News
- 12 days ago - DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT™ Blood System in Routine Clinical Practice - Business Wire
- 23 days ago - Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook - Business Wire
- 7 weeks ago - Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America - Business Wire
- 2 months ago - Cerus: IFC Growth And RBC Optionality - Seeking Alpha
- 3 months ago - Cerus Corporation (CERS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance - Business Wire
- 3 months ago - Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting - Business Wire
- 3 months ago - Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire